Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors.
Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, Van Riel PL. Fransen J, et al. Among authors: kavanaugh a. Ann Rheum Dis. 2006 Oct;65(10):1373-8. doi: 10.1136/ard.2006.051706. Epub 2006 Apr 27. Ann Rheum Dis. 2006. PMID: 16644783 Free PMC article.
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C; IMPACT 2 Study Group. Kavanaugh A, et al. Ann Rheum Dis. 2007 Apr;66(4):498-505. doi: 10.1136/ard.2006.058339. Epub 2006 Nov 17. Ann Rheum Dis. 2007. PMID: 17114188 Free PMC article. Clinical Trial.
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A. van der Heijde D, et al. Among authors: kavanaugh a. Arthritis Rheum. 2007 Aug;56(8):2698-707. doi: 10.1002/art.22805. Arthritis Rheum. 2007. PMID: 17665424 Free article. Clinical Trial.
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D. Smolen J, et al. Among authors: kavanaugh a. Ann Rheum Dis. 2009 Jun;68(6):797-804. doi: 10.1136/ard.2008.101659. Epub 2008 Nov 17. Ann Rheum Dis. 2009. PMID: 19015207 Free PMC article. Clinical Trial.
Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.
Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. Kavanaugh A, et al. Ann Rheum Dis. 2015 Jan;74(1):44-51. doi: 10.1136/annrheumdis-2014-205198. Epub 2014 Jun 18. Ann Rheum Dis. 2015. PMID: 24942382 Free PMC article. Clinical Trial.
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JW, Burmester GR, Cronstein B, Keystone EC, Kavanaugh A, Klareskog L. Furst DE, et al. Among authors: kavanaugh a. Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii2-7. doi: 10.1136/ard.61.suppl_2.ii2. Ann Rheum Dis. 2002. PMID: 12379612 Free PMC article. Review. No abstract available.
584 results